Cargando…
Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: Is it still useful outside the clinical trial setting?
BACKGROUND: Posaconazole prophylaxis during remission induction chemotherapy not only decreases the incidence of invasive aspergillosis (IA) but also improves the overall survival rate among patients with acute myeloid leukemia (AML). However, it remains debatable whether this result applies to pati...
Autores principales: | Chen, Tsung-Chih, Wang, Ren Ching, Lin, Yu-Hui, Chang, Kuang-Hsi, Hung, Li-Ya, Teng, Chieh-Lin Jerry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607783/ https://www.ncbi.nlm.nih.gov/pubmed/33194163 http://dx.doi.org/10.1177/2040620720965846 |
Ejemplares similares
-
Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011) -
Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020) -
Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis
por: Calmettes, Claire, et al.
Publicado: (2018) -
The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study
por: Özkocaman, Vildan, et al.
Publicado: (2018) -
Economic analysis of oral posaconazole prophylaxis in acute myeloid leukemia during remission induction in Turkey
por: Umit, Elif Gulsum, et al.
Publicado: (2020)